Cargando…

Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy

BACKGROUND: This study aimed to evaluate the risk factors of HCC development in patients with hepatitis B virus (HBV)-related DC and who underwent long-term antiviral therapy. METHODS: Data from 308 patients with HBV-related DC and long-term antiviral therapy were collected and retrospectively revie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Dong-Mei, Xie, Jing, Ye, Chun-Yan, Qian, Mei-Yun, Xue, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762653/ https://www.ncbi.nlm.nih.gov/pubmed/33381476 http://dx.doi.org/10.1155/2020/8871024

Ejemplares similares

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
por: Mao, Hao-dan, et al.
Publicado: (2023)

Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis
por: Ju, Young-Cheol, et al.
Publicado: (2018)

Prognostic value of albumin‐related ratios in HBV‐associated decompensated cirrhosis
por: Zhang, Tan, et al.
Publicado: (2022)

Serum Cystatin C Predicts Mortality in HBV-Related Decompensated Cirrhosis
por: Wu, JianPing, et al.
Publicado: (2019)

Serum potassium levels and prognosis in HBV‐associated decompensated cirrhosis
por: Huang, JianJiang, et al.
Publicado: (2021)

Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy
por: Nam, Joon Yeul, et al.
Publicado: (2020)

Long-term administration of Tolvaptan to patients with decompensated cirrhosis
por: Kanayama, Kengo, et al.
Publicado: (2020)

Neutrophil-to-Lymphocyte Ratio Predicts Early Mortality in Patients with HBV-Related Decompensated Cirrhosis
por: Zhang, Honggang, et al.
Publicado: (2016)

Serum C-reactive protein predicts early mortality in hospitalized patients with HBV-related decompensated cirrhosis
por: Zhu, ShaoMing, et al.
Publicado: (2017)

Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
por: Liu, Jian, et al.
Publicado: (2023)

Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis
por: Gurbuz, Berivan, et al.
Publicado: (2023)

Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis
por: Wang, Tongyu, et al.
Publicado: (2022)

Hepatopulmonary syndrome is associated with the presence of hepatocellular carcinoma in patients with decompensated cirrhosis
por: Soulaidopoulos, Stergios, et al.
Publicado: (2017)

Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy
por: Li, Mingyu, et al.
Publicado: (2023)

Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study
por: Lapointe-Shaw, Lauren, et al.
Publicado: (2018)

FXYD6 overexpression in HBV-related hepatocellular carcinoma with cirrhosis
por: Chen, Xiongfei, et al.
Publicado: (2020)

The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma
por: Yu, Liang-He, et al.
Publicado: (2011)

Neutrophil count to albumin ratio as a prognostic indicator for HBV‐associated decompensated cirrhosis
por: Han, Zhong, et al.
Publicado: (2021)

Frequency of hepatic HBV-DNA in patients with cirrhosis and hepatocellular carcinoma: relation to serum HBV markers.
por: White, Y. S., et al.
Publicado: (1990)

Serum Zonulin in HBV-Associated Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma
por: Wang, Xin, et al.
Publicado: (2019)

Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis
por: VoPham, Trang, et al.
Publicado: (2023)

Mean Platelet Volume/Lymphocyte Ratio as a Prognostic Indicator for HBV-Related Decompensated Cirrhosis
por: Wu, JianPing, et al.
Publicado: (2020)

Long-term albumin infusion in decompensated cirrhosis: A review of current literature
por: Wong, Yu Jun, et al.
Publicado: (2021)

Combination with portosystemic shunt occlusion and antiviral therapy improves prognosis of decompensated cirrhosis
por: Tamai, Hideyuki, et al.
Publicado: (2020)

Plasma D-dimer as a novel biomarker for predicting poor outcomes in HBV-related decompensated cirrhosis
por: Zhou, Jing, et al.
Publicado: (2019)

Compression from an enlarged spleen in decompensated cirrhosis mimicking the appearance of fundal varices
por: Lin, Xue-Mei, et al.
Publicado: (2023)

Comment on “Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis”
por: Mo, Han-Yue, et al.
Publicado: (2016)

Hepatic Venous Pressure Gradient Predicts Long-Term Mortality in Patients with Decompensated Cirrhosis
por: Kim, Tae Yeob, et al.
Publicado: (2016)

Hepatic Hydrothorax—An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis
por: Matei, Daniela, et al.
Publicado: (2021)

Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis
por: Ji, Fanpu, et al.
Publicado: (2013)

Platelet‐to‐white blood cell ratio: A novel and promising prognostic marker for HBV‐associated decompensated cirrhosis
por: Zhang, JinFei, et al.
Publicado: (2020)

Low Hemoglobin-to-Red Cell Distribution Width Ratio Is Associated with Mortality in Patients with HBV-Related Decompensated Cirrhosis
por: Yu, Ze, et al.
Publicado: (2022)

Increased Serum Levels of sCD206 Are Associated with Adverse Prognosis in Patients with HBV-Related Decompensated Cirrhosis
por: Zhang, Yue, et al.
Publicado: (2022)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis
por: Bi, Jingfeng, et al.
Publicado: (2017)

Improving Survival in Decompensated Cirrhosis
por: Mukerji, Amar Nath, et al.
Publicado: (2012)

Management options in decompensated cirrhosis
por: Shah, Neeral L, et al.
Publicado: (2015)

COVID-19 in decompensated cirrhosis
por: Rela, Mohamed, et al.
Publicado: (2020)

Decompensation of Cirrhosis: An Unusual Cause
por: Rudra, Omkar S, et al.
Publicado: (2022)

Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study
por: Pereira, Gustavo H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mo88kgan66q74gs1nlqh7bbqsp